Table 1 Clinical information of the eligible trials for the meta-analysis

Dong 2009 [24]

127

CIK (3 course)

41 (31)

1.0-2.0 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

CIK (6 course)

43 (32)

Surgery only

43 (34)

Weng 2008 [20]

85

TACE + RFA + CIK

45 (31)

1.0-1.5 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + RFA

40 (29)

Zhao 2006 [21]

64

TACE + RFA

31 (29)

1.1-1.5 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + RFA + CIK

33 (30)

Pan 2010 [22]

83

TACE + RFA + CIK

42 (37)

> 1.0 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + RFA

41 (34)

Hao 2010 [19]

146

TACE

74 (64)

1.0-5.0 × 10¹⁰ per course

SFM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + CIK

72 (65)

Lu 2008 [25]

30

CIK

12 (UK)

1.6 × 10¹⁰ per course

SFM, IFN-γ, CD3McAb, IL-1a, IL-2

Surgery alone

18 (UK)

Zhang 2007 [16]

44

TACE

20 (UK)

8.0 × 10⁹ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + CIK

24(UK)

Guo 2007 [17]

61

TACE

31 (UK)

1.0-1.2 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + CIK

30 (UK)

Zhang 2006 [27]

144

TACE

30 (UK)

1.0-1.2 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a IL-2

TACE + CIK

16 (UK)

TACE + PEI

62 (UK)

TACE + PEI + CIK

36 (UK)

Shi 2007 [28]

252

TACE

134 (UK)

1.0-1.2 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + PEI

80 (UK)

TACE + CIK

38 (UK)

Hao 2006 [18]

67

TACE + CIK

21 (17)

1.0-5.0 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE

46 (45)

Wan 2008 [23]

61

TACE + RFA

34 (23)

1.0 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

TACE + RFA + CIK

27 (18)

Yu 2009 [26]

50

TACE + CIK

25 (22)

1.0-1.2 × 10¹⁰ per course

CM, IFN-γ, CD3McAb, IL-1a, IL-2

Surgery alone

25 (23)